Gilead Appoints James Rooney and Alan Taylor to Vice President Positions.FOSTER CITY, Calif.--(BUSINESS WIRE)--Aug. 6, 1996--Gilead Sciences, Inc. (Nasdaq:GILD) announced today the appointments of James F. Rooney, M.D., as Vice President, Clinical Affairs, and Alan S. Taylor, Ph.D., as Vice President, Drug Assessment. Dr. Rooney will oversee Gilead's clinical development programs, and Dr. Taylor will be responsible for toxicological assessment of preclinical compounds and for regulatory affairs. Drs. Rooney and Taylor report to Howard S. Jaffe, M.D., who has been appointed to the newly created position of Senior Vice President, Drug Development. Dr. Jaffe, 38, previously served as Gilead's Vice President, Clinical Affairs and Chief Medical Officer. Dr. Jaffe has been with Gilead Sciences since 1991. From 1992 until he joined Gilead, Dr. Rooney, 44, was with Glaxo Wellcome (formerly Burroughs Wellcome), where he provided medical support for the development of new compounds for the treatment of HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. and herpes simplex virus Herpes simplex virus A virus that can cause fever and blistering on the skin, mucous membranes, or genitalia. Mentioned in: Conjunctivitis herpes simplex virus (HSV (Hue Saturation Value) A color space similar to HSB. See HSB. HSV - hue, saturation, value ) infections. He served most recently as Glaxo Wellcome's Director of HIV and Opportunistic Infections. From 1982 to 1992, he held positions at the National Institutes of Health, where he specialized in the pathogenesis and treatment of HSV and HIV infections. Dr. Rooney received his M.D. from the University of Maryland University of Maryland can refer to:
From 1995 until he joined Gilead, Dr. Taylor, 40, was a senior clinical and regulatory consultant at BRI International, a contract research organization. From 1988 to 1995, Dr. Taylor was with the U.S. Food and Drug Administration (FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. ). Most recently, he served as Assistant Director for Pharmacology and Toxicology in the Center for Drug Evaluation and Research The Center for Drug Evaluation and Research is a division of the FDA that deals with the approval of drugs. CDER reviews New Drug Applications to ensure that the drugs are safe and effective. It is one of five Centers at the United States Food and Drug Administration. (CDER), as Chairman of the Carcinogenicity Assessment Committee (CAC See Consumer Advisory Council. ) and as the FDA's senior representative to the International Conference on Harmonization Safety Working Group, responsible for developing international guidelines for preclinical testing. From 1985 to 1988, Dr. Taylor was with the National Institutes of Health. He received his Ph.D. in Pharmacology from Washington University, St. Louis. "Gilead is fortunate to have added the expertise of both Jim Rooney and Alan Taylor to our talented development team," said John C. Martin, Ph.D., President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Gilead. "Dr. Rooney's experience in the area of clinical development and his special expertise in HIV and related drug development is particularly advantageous at a time when our company is moving rapidly ahead with product candidates for patients with AIDS. Dr. Taylor's extensive knowledge and in-depth experience in the areas of pharmacology, toxicology and regulatory affairs will be of important benefit in the preclinical and clinical development, as well as regulatory review, of our broad and deep product pipeline." Gilead Sciences is committed to developing important human therapeutics to treat viral infections. Gilead's first product, VISTIDE(R) (cidofovir injection), was granted marketing clearance by the U.S. Food and Drug Administration in June 1996 for the treatment of cytomegalovirus (CMV) retinitis in patients with AIDS. In addition, the Company has other nucleotide product candidates in human testing for the potential treatment of viral diseases caused by CMV, human immunodeficiency virus human immunodeficiency virus n. HIV. Human immunodeficiency virus (HIV) A transmissible retrovirus that causes AIDS in humans. (HIV), herpes simplex virus, human papillomavirus and hepatitis B virus. Gilead Sciences is a leader in the discovery and development of a new class of human therapeutics based on nucleotides, the building blocks of DNA DNA: see nucleic acid. DNA or deoxyribonucleic acid One of two types of nucleic acid (the other is RNA); a complex organic compound found in all living cells and many viruses. It is the chemical substance of genes. and RNA. The Company's research and development efforts encompass three interrelated programs: small molecule antivirals, cardiovascular therapeutics and genetic code blockers for cancer and other diseases. Gilead's expertise in each of these areas has also resulted in the discovery of non-nucleotide product candidates that expand the Company's technology platforms. Gilead common stock is traded on The Nasdaq Stock Market Nasdaq stock market The first electronic stock market listing over 5000 companies. The Nasdaq stock market comprises two separate markets, namely the Nasdaq National Market, which trades large, active securities and the Nasdaq Smallcap Market that trades emerging growth companies. under the symbol GILD. -0- Note to editors: Additional written materials and recent releases are available through the Gilead Fax-On-Demand Information Service by dialing 1-800-276-7318. CONTACT: Gilead Sciences, Inc. Lana Lauher, 415/573-4858 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion